Open AccessAdjuvant chemotherapy with gemcitabine plus erlotinib vs. gemcitabine alone for patients with resected pancreatic ductal adenocarcinoma: is there a role for erlotinib?—review of the open label phase III trial CONKO 005
Author(s) -
Mathilde Wisniewski,
Pierre-Alain Placide,
Sandra Granier,
Yacoub Al Shatti,
Shuaib Al Qalaf,
Mohamed Bouattour,
Michèle Lamuraglia,
Pascal Hammel
Publication year - 2018
Publication title -
hepatobiliary surgery and nutrition
Language(s) - English
Resource type - Journals
eISSN - 2304-389X
pISSN - 2304-3881
DOI - 10.21037/hbsn.2018.08.03
Subject(s) - erlotinib , gemcitabine , medicine , pancreatic ductal adenocarcinoma , oncology , pancreatic cancer , erlotinib hydrochloride , chemotherapy , adenocarcinoma , adjuvant , adjuvant chemotherapy , open label , clinical trial , cancer , epidermal growth factor receptor , breast cancer